JPRN-UMIN000023422已完成2 期
A phase two clinical trial of the personalized peptide vaccine for standard therapy-resistant pediatric cancer patients - A phase two trial of peptide vaccine for standard therapy-resistant pediatric cancer patients
Kurume University Cancer Vaccine Center0 个研究点目标入组 50 人开始时间: 2016年8月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 3years-old 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The following patients must be excluded : 1) Patients with severe symptoms (active and severe infections, circulatory disease, respiratory disease, kidney disease,immunodeficiency, disturbance of coagulation). 2) Active double cancer (synchronous double cancer and meta-chronous double cancer within 3 disease-free years),excluding carcinoma in situ (lesions equal to intra-epithelial or intra-mucosal cancer) judged to have been cured with local treatment. 3) Patients with leukemia 4) Patients with the past history of severe allergic reactions. 5) Patients who hope for pregnancy 6) Patients who do not accept contraception from the 1st vaccination until 70 days after the last vaccination. 7) Patients who are judged inappropriate for entry to this trial by doctors.
研究者
相似试验
已完成
2 期
A phase two clinical trial of the personalized peptide vaccine for the recurrence prevention in pediatric cancer patientsPediatric cancer patientsJPRN-UMIN000030249Kurume University Cancer Vaccine Center50
已完成
2 期
A randomised phase II trial of personalized peptide vaccination plus "Keppuchikuoto" vs personalized peptide vaccination alone for non small cell lung cancer patientsnresectable non smaii cell lung cancerJPRN-UMIN000015173Kurume Unversity Cancer Vaccine Center60
已完成
2 期
Phase II randomised clinical trial of personalized peptide vaccination in combination with Dai-kenchu-to for colorectal cancer patients resistant to standard therapies.colorectal cancerJPRN-UMIN000008126Kurume University Cancer Vaccine Center60
已完成
2 期
Phase II randomised clinical trial of personalized peptide vaccination in combination with Ninjin-yoei-to for lung cancer patients resistant to standard therapies .lung cancerJPRN-UMIN000008940Kurume University Cancer Vaccine Center80
已完成
2 期
Phase II randomised clinical trial of personalized peptide vaccination in combination with Juzen-taiho-to for gastric cancer patients resistant to standard therapies .gastric cancerJPRN-UMIN000008827Kurume University Cancer Vaccine Center60